No tax




Security policy (edit with Customer reassurance module)


Delivery policy (edit with Customer reassurance module)


Return policy (edit with Customer reassurance module)

Active ingredient: Taurine - 500 mg.

Auxiliary components:

povidone - 57.0 mg, microcrystalline cellulose - 18.0 mg, croscarmellose sodium - 17.2 mg, Calcium stearate - 4.8 mg, colloidal silicon dioxide - 3.0 mg.

Pharmacological properties

Taurine is a natural product of the exchange of sulfur-containing amino acids: cysteine, cysteamine, methionine. Taurine has osmoregulatory and membrane-protective properties, has a positive effect on the phospholipid composition of cell membranes, and normalizes the exchange of calcium and potassium ions in cells. Taurine has been shown to have inhibitory neurotransmitter properties, it has anti-stress effect, it can regulate the release of gamma-aminobutyric acid (GABA), adrenaline, prolactin and other hormones, as well as regulate the responses to them. Participating in the synthesis of proteins of the respiratory chain in mitochondria, taurine regulates oxidative processes and exhibits antioxidant properties; affects enzymes such as cytochromes involved in the metabolism of various xenobiotics.
Taurine improves metabolic processes in the heart, liver and other organs and tissues. In chronic diffuse liver diseases, taurine increases blood flow and reduces the severity of cytolysis.

Treatment with CardioActiv Taurine in case of cardiovascular insufficiency (CSN) leads to a decrease in stagnation in the small and large circulation circles:

intracardiac diastolic pressure decreases, myocardial contractility increases (maximum rate of contraction and relaxation, contractility and relaxation indices). The drug moderately reduces blood pressure (BP) in patients with arterial hypertension and has virtually no effect on blood pressure in patients with cardiovascular insufficiency with low BP.

CardioActive Taurine reduces the side effects that occur when an overdose of cardiac glycosides and blockers of "slow" calcium channels; reduces the hepatotoxicity of antifungal drugs. Increases performance with heavy physical exertion.

In diabetes mellitus, approximately 2 weeks after the start of the administration of the drug CardioActive Tuarin, the concentration of glucose in the blood decreases. A significant decrease in the concentration of triglycerides, to a lesser extent, of cholesterol concentration, a decrease in plasma lipid atherogenicity has also been observed. With prolonged use of the drug (about 6 months) marked improvement in the microcirculatory blood flow of the eye.

Indications for use

- The drug is used in complex therapy:

- cardiovascular insufficiency of various etiologies;

- intoxication caused by taking cardiac glycosides;

- type 1 diabetes;

- diabetes mellitus type 2, including with moderate hypercholesterolemia.


- Severe heart failure in the stage of decompensation.

- Hypersensitivity to the drug.

- CardioActive Tuarin is not recommended for use in children under the age of 18 years due to - lack of data on efficacy and safety.

Precautions for use

Use with caution in patients with severely impaired renal function, while being used with cardiac glycosides, slow calcium channel blockers (BMCCs).

Use during pregnancy and during breastfeeding

The use of the drug CardioActive Taurine during pregnancy and during breastfeeding is not recommended due to the lack of sufficient clinical experience in this category of patients.

Dosage and administration

Before using the drug consult a doctor.

In heart failure, CardioActive Taurine is taken orally on 250-500 mg (1/2 - 1 tablet) 2 times a day 20 minutes before meals, the course of treatment is 30 days. The dose can be increased to 2-3 g (4-6 tablets) per day.

With intoxication with cardiac glycosides - not less than 750 mg (1.5 tablets) per day.

With type 1 diabetes, 500 mg (1 tablet) 2 times a day in combination with insulin therapy for 3-6 months.

In case of type 2 diabetes mellitus, 500 mg (1 tablet) 2 times a day in combination with diet therapy or other hypoglycemic oral preparations.

In case of diabetes mellitus type 2, including those with moderate hypercholesterolemia, 500 mg (1 tablet) 2 times a day.

Side effect

Allergic reactions to the drug components are possible.


Data overdose available.

Interaction with other drugs

CardioActive Taurine can be used with other medicines.
Taurine enhances the inotropic effect of cardiac glycosides.

special instructions

With complex treatment of heart failure, diabetes mellitus, cardiac glycoside intoxication, the drug is administered under the supervision of a physician.
The drug does not affect the performance of potentially hazardous activities that require increased concentration of attention and speed of psychotropic reactions (driving, working with moving mechanisms, the work of the dispatcher, operator, etc.).

Release form

Tablets 500 mg. On 20 pills in a blister strip packaging from a film of polyvinyl chloride and flexible packaging made on the basis of aluminum foil. 2 or 3 blister packs together with instructions for use are placed in a pack of cardboard.

Storage conditions

Store at a temperature not higher than 25 ° С. Keep out of the reach of children.

32 Items